The estimated Net Worth of Keith Murphy is at least $8.53 Million dollars as of 22 November 2017. Mr. Murphy owns over 335,500 units of Organovo Inc stock worth over $3,502,971 and over the last 12 years he sold ONVO stock worth over $4,915,750. In addition, he makes $108,124 as Executive Chairman and Principal Executive Officer at Organovo Inc.
Sign up
Mr. Murphy ONVO stock SEC Form 4 insiders trading
Keith has made over 10 trades of the Organovo Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 335,500 units of ONVO stock worth $499,895 on 22 November 2017.
The largest trade he's ever made was buying 335,500 units of Organovo Inc stock on 22 November 2017 worth over $499,895. On average, Keith trades about 32,017 units every 50 days since 2012. As of 22 November 2017 he still owns at least 6,373,673 units of Organovo Inc stock.
You can see the complete history of Mr. Murphy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Keith Murphy biography
Keith E. Murphy serves as Executive Chairman and Principal Executive Officer of the Company. He re-joined our Board in July 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc., a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the President and Chief Executive Officer of Organovo from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., Organovo’s primary operating company prior to its going-public transaction, from August 2007 to February 2012. Prior to founding Organovo, Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. He holds a BS in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy’s previous experience in the biotechnology field, especially in developing novel products, his experience and expertise with our 3D bioprinting technology and product development opportunities and strategy, and his educational experience qualify him to be a member of our Board of Directors.
What is the salary of Keith Murphy?
As the Executive Chairman and Principal Executive Officer of Organovo Inc, the total compensation of Keith Murphy at Organovo Inc is $108,124. There are 1 executives at Organovo Inc getting paid more, with Steven Hughes having the highest compensation of $1,313,490.
How old is Keith Murphy?
Keith Murphy is 48, he's been the Executive Chairman and Principal Executive Officer of Organovo Inc since 2020. There are 2 older and 1 younger executives at Organovo Inc. The oldest executive at Organovo Holdings Inc is Adam Stern, 56, who is the Independent Director.
What's Keith Murphy's mailing address?
Keith's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121.
Insiders trading at Organovo Inc
Over the last 13 years, insiders at Organovo Inc have traded over $8,085,375 worth of Organovo Inc stock and bought 386,250 units worth $661,443 . The most active insiders traders include Mark Kessel, Keith Murphy, and Adam K Stern. On average, Organovo Inc executives and independent directors trade stock every 112 days with the average trade being worth of $29,354. The most recent stock trade was executed by David Gobel on 15 November 2023, trading 19,607 units of ONVO stock currently worth $31,763.
What does Organovo Inc do?
organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.
What does Organovo Inc's logo look like?
Complete history of Mr. Murphy stock trades at Organovo Inc
Organovo Inc executives and stock owners
Organovo Inc executives and other stock owners filed with the SEC include:
-
Steven Hughes,
Chief Medical Officer -
Keith Murphy,
Executive Chairman and Principal Executive Officer -
Steve Kunszabo,
VP, Investor Relations & Corporate Communications -
Adam Stern,
Independent Director -
Alison Milhous,
Independent Director -
David Gobel,
Independent Director -
Douglas Cohen,
Independent Director -
Thomas Jurgensen,
General Counsel -
Jeffrey Miner,
Chief Scientific Officer -
Chris Heberlig,
President, Chief Financial Officer -
David Shapiro,
Director -
Craig Kussman,
Chief Financial Officer -
Robert Jr. Baltera,
Director -
Paul Gallant,
General Manager -
Jennifer Bush,
General Counsel & Secretary -
Kirk Malloy,
Director -
Mark Kessel,
Director -
Taylor Crouch,
CEO & President -
James T Glover,
Director -
Sharon Collins Presnell,
Chief Scientific Officer -
Richard E Maroun,
Director -
Tamar D Howson,
Director -
Kevin Kimberlin,
10% owner -
Richard A. Heyman,
Director -
Michael Renard,
EVP of Commercial Operations -
Andras Forgacs,
Director -
Barry D Michaels,
Chief Financial Officer -
Eric David,
CSO & EVP Pre-Clinical Dev -
Carolyn Beaver,
Director -
Vaidehi Joshi,